GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
- None.
- None.
The extension of sensor longevity in Glucotrack's Continuous Blood Glucose Monitor (CBGM) represents a significant advancement in diabetes care technology. The ability for a sensor to last beyond three years, as opposed to the previously projected two, could potentially reduce the frequency of invasive procedures required for sensor replacement, thereby enhancing patient comfort and compliance. Furthermore, longer-lasting sensors may diminish the long-term cost burden for patients, as the need for replacements diminishes.
From a business perspective, this technological edge could position Glucotrack as a leader in the glucose monitoring market, potentially increasing its market share. However, it is essential to consider that the computational modeling, while promising, is not a guarantee of real-world performance. The actual sensor longevity will need to be validated through extensive clinical trials and real-world usage data before the claims can be fully substantiated.
Moreover, the announcement does not indicate an immediate impact on commercialization timing, suggesting that the company's revenue forecasts remain unchanged in the short term. Investors should be aware that the long-term benefits, while potentially substantial, carry a degree of uncertainty until further data is available.
The use of in silico modeling to predict enzyme longevity in electrochemical sensors is a sophisticated approach that leverages computational power to anticipate the performance of biomedical devices. TTP's expertise in multiphysics modeling and electrochemical sensor development is important in accurately simulating in-vivo conditions and predicting the sensor's lifespan. This collaboration underscores the importance of interdisciplinary partnerships in advancing medical technology.
Understanding the technical aspects, such as the rate of glucose transport and the consumption of enzyme, is vital for investors as it provides insight into the robustness of the underlying technology. The use of cardiovascular technology to measure blood glucose intravenously and provide rapid results without the lag associated with interstitial sensors could be a game-changer for real-time diabetes management.
However, it is important to recognize that the transition from modeling to actual device performance involves numerous challenges, including regulatory approval processes and potential unforeseen biological variables that could affect sensor longevity. Investors should consider these factors when evaluating the potential market impact of Glucotrack's CBGM technology.
The diabetes care market is highly competitive, with continuous innovation driving growth. Glucotrack's announcement could signal a strategic advantage over competitors if the sensor's extended longevity translates to a superior product offering. The ability to offer a long-term CBGM system aligns with the industry's move towards more patient-centric and cost-effective solutions.
However, the actual market impact will depend on several factors, including the sensor's performance in clinical trials, its cost relative to competitors and the adoption rate among healthcare providers. Additionally, the company's ability to effectively communicate the benefits of their product to end-users and healthcare professionals will be critical for market penetration.
Investors should monitor subsequent developments, particularly regulatory approvals and partnerships with healthcare providers, as these will be indicative of the technology's potential to disrupt the market and generate returns.
Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced
Implantable Continuous Blood Glucose Monitor technology could transform lives of patients with diabetes
Rutherford, NJ & Cambridge, UK, April 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership (“TTP”), today announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor (“CBGM”), suggesting sensor longevity beyond three years, a year longer than the Company previously announced.
Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation. The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.
Previously, Glucotrack had announced a projected sensor longevity of 2+ years. TTP’s modeling confirmed the 2+ year projection, but TTP’s modeling further projects that the Glucotrack CBGM sensor longevity may now be capable of reaching 3+ years. The model developed by TTP captures numerous processes and complex aspects of the sensor function, including the rate of glucose transport in typical in-vivo conditions, the consumption of enzyme, and the impact of reaction components while incorporating appropriate benchtop sensor data.
TTP brings over 35 years of experience in the life science and healthcare sectors to this project, with specific expertise in multiphysics modeling, electrochemical sensor development, and the design and integration of wearable and implantable medical devices. TTP’s knowledge and skills have been instrumental in evaluating and extending the projected longevity of the Glucotrack CBGM sensor.
"TTP is well versed in supporting clients with creating breakthrough medical technology solutions,” said Paul Goode, PhD, CEO of Glucotrack. “This collaboration has enhanced our development program, and the projected increase in sensor longevity to beyond three years further demonstrates that our technology is truly differentiated in the glucose monitoring space. This achievement doesn’t change our commercialization timing but instead paves the way for future generations of our system, which will be a truly long-term CBGM to people living every day with diabetes.”
Chris Dawson, PhD, Head of Biosensing at TTP, said: “We are delighted to be working on this exciting and disruptive technology with Glucotrack. These tremendously promising results, coupled with Glucotrack’s innovative approach to glucose monitoring, means that this technology has the potential to deliver a new way for patients to manage their diabetes with discretion and minimal disruption to their lives.”
For more information about Glucotrack’s CBGM, visit glucotrack.com.
# # #
About GlucoTrack, Inc.
GlucoTrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
GlucoTrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
About The Technology Partnership
The Technology Partnership is an internationally respected product and technology development firm based in Cambridge, UK. For over 35 years, clients across a spectrum of industries including health tech, life science, deep tech and clean tech have trusted its deep domain expertise and enabling culture to create valuable new technology and deliver ground-breaking solutions, from first principles, through product design and manufacture to commercialisation. Please visit https://www.ttp.com/.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and GlucoTrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by the GlucoTrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect GlucoTrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect GlucoTrack’s results include, but are not limited to, the ability of GlucoTrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to GlucoTrack’s current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in GlucoTrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2023.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucoTrackPR@icrinc.com
